/
DRUG
$60.22-$3.16 (-4.99%)live
Change+$18.92
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$621.9M
10M shares
52-week range
$44.25 – $123.75
20% from low
Exchange
NASDAQ
CS
Bright Minds Biosciences Inc. Common Stock
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
www.brightmindsbio.com- Employees
- 25
- IPO / List date
- Mar 8, 2021
Held by traders on TradeandTell
No one on the platform currently holds DRUG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 3,500 | $212.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-07-14 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded DRUG yet.
